May 13, 2026 16:30 ET Châtillon, France, May 13, 2026 Combined General Meeting of June 3, 2026 Procedures for Obtaining Information and Preparatory Documents for the Combined General Meeting DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market:...
May 12, 2026 16:30 ET Châtillon, France, May 12, 2026 DBV Technologies to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market:...
April 30, 2026 16:30 ET Châtillon, France, April 30, 2026 DBV Technologies Reports First Quarter 2026 Financial Results Reported cash and cash equivalents of $229 million as of March 31, 2026 —providing funding into the second quarter of 2027 following the full exercise of the ABSA Warrants and BS Warrants issued in its March 2025 private placement...
April 02, 2026 16:30 ET Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of March 31, 2026 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Paris ISIN Code:...
March 26, 2026 17:19 ET Châtillon, France, March 26, 2026 DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market:...
March 26, 2026 17:06 ET Châtillon, France, March 26, 2026 DBV Technologies Reports Full Year 2025 Financial Results and Business Update Continued advancing the VIASKIN ® Peanut Patch clinical development programs in peanut-allergic toddlers (1 through 3 years old) and children (4 through 7 years old) Bolstered executive leadership team in...
March 24, 2026 16:30 ET Châtillon, France, March 24, 2026 DBV Technologies to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review Changes went into effect on Monday, March 23, 2026 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market:...
March 04, 2026 16:30 ET Châtillon, France, March 4, 2026 DBV Technologies to Participate in Upcoming March Investor Conferences DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company, today announced the company will participate at the following investor conferences in March:...
March 03, 2026 16:30 ET Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of February 28, 2026 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Paris ISIN Code:...
February 28, 2026 14:25 ET Châtillon, France, February 28, 2026 DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting Approximately 83% of children treated with the VIASKIN ® Peanut Patch increased their eliciting dose at month 12, compared to approximately 48% in the placebo group Approximately...